Literature DB >> 20439289

The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis.

Diane van der Woude1, Silje W Syversen, Ellen I H van der Voort, Kirsten N Verpoort, Guro L Goll, Michael P M van der Linden, Annette H M van der Helm-van Mil, Désirée M F M van der Heijde, Tom W J Huizinga, Tore K Kvien, René E M Toes.   

Abstract

BACKGROUND: The presence of anti-citrullinated protein antibodies (ACPA) is a powerful predictive factor for the development and progression of rheumatoid arthritis (RA). The ACPA response has been shown to consist of various isotypes, but the consequences of differences in isotype distribution have not been extensively investigated.
OBJECTIVE: To investigate the relationship between ACPA isotypes, disease progression and radiological outcome.
METHODS: ACPA isotypes were determined in sera of anti-cyclic citrullinated peptide 2-positive patients by enzyme-linked immunosorbent assay (ELISA). To investigate whether the ACPA response continues to evolve during disease development, the ACPA isotype profile during progression of undifferentiated arthritis (UA) to RA was studied. The association of disease progression with ACPA isotype use was assessed using long-term radiographic follow-up data from patients with RA in two independent cohorts.
RESULTS: The ACPA isotype distribution did not expand during disease progression from UA to RA, but was relatively stable over time. In both RA cohorts, the baseline ACPA isotype profile was a significant predictor of disease severity, with more isotypes indicating a higher risk of radiographic damage (odds ratio for every additional isotype: 1.4 (95% CI 1.1 to 1.9) p<0.001). ACPA isotypes supplied additional prognostic information to ACPA status alone, even after correction for other predictive factors.
CONCLUSIONS: The magnitude of the ACPA isotype profile at baseline reflects the risk of future radiographic damage. These results indicate that the presence and the constitution of the ACPA response are relevant to the disease course of RA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20439289     DOI: 10.1136/ard.2009.116384

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  32 in total

Review 1.  New tools for classification and monitoring of autoimmune diseases.

Authors:  Holden T Maecker; Tamsin M Lindstrom; William H Robinson; Paul J Utz; Matthew Hale; Scott D Boyd; Shai S Shen-Orr; C Garrison Fathman
Journal:  Nat Rev Rheumatol       Date:  2012-05-31       Impact factor: 20.543

Review 2.  The pathogenic potential of autoreactive antibodies in rheumatoid arthritis.

Authors:  Marieke Bax; Tom W J Huizinga; René E M Toes
Journal:  Semin Immunopathol       Date:  2014-04-25       Impact factor: 9.623

3.  Do Genetic Susceptibility Variants Associate with Disease Severity in Early Active Rheumatoid Arthritis?

Authors:  Ian C Scott; Frühling Rijsdijk; Jemma Walker; Jelmar Quist; Sarah L Spain; Rachael Tan; Sophia Steer; Yukinori Okada; Soumya Raychaudhuri; Andrew P Cope; Cathryn M Lewis
Journal:  J Rheumatol       Date:  2015-05-15       Impact factor: 4.666

4.  Changes in anti-citrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early rheumatoid arthritis.

Authors:  A Kastbom; K Roos Ljungberg; M Ziegelasch; J Wetterö; T Skogh; K Martinsson
Journal:  Clin Exp Immunol       Date:  2018-10-14       Impact factor: 4.330

5.  Rheumatoid arthritis: Autoantibody testing to predict response to therapy in RA.

Authors:  Leendert A Trouw; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2016-09-15       Impact factor: 20.543

6.  Immunoglobulin (Ig)G1 and IgG4 anti-cyclic citrullinated peptide (CCP) associate with shared epitope, whereas IgG2 anti-CCP associates with smoking in patients with recent-onset rheumatoid arthritis (the Swedish TIRA project).

Authors:  K Martinsson; A Johansson; A Kastbom; T Skogh
Journal:  Clin Exp Immunol       Date:  2017-01-10       Impact factor: 4.330

Review 7.  Biomarkers in connective tissue diseases.

Authors:  Neelakshi R Jog; Judith A James
Journal:  J Allergy Clin Immunol       Date:  2017-12       Impact factor: 10.793

Review 8.  The influence of ACPA status and characteristics on the course of RA.

Authors:  Annemiek Willemze; Leendert A Trouw; René E M Toes; Tom W J Huizinga
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

9.  Label-free detection of immune complexes with myeloid cells.

Authors:  Z Szittner; A E H Bentlage; P Rovero; P Migliorini; V Lóránd; J Prechl; G Vidarsson
Journal:  Clin Exp Immunol       Date:  2016-05-12       Impact factor: 4.330

10.  Resistin in inflammatory and degenerative rheumatologic diseases. Relationship between resistin and rheumatoid arthritis disease progression.

Authors:  S M H Fadda; S M Gamal; N Y Elsaid; A M Mohy
Journal:  Z Rheumatol       Date:  2013-08       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.